Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
March 18, 2025 | 05:52
Telix Pharmaceuticals Limited today announces that the Brazilian Health Regulatory Agency has approved Illuccix® the Company's lead prostate cancer imaging agent.
Illuccix Approved in the United Kingdom
February 13, 2025 | 04:30
Telix Pharmaceuticals Limited today announces that the United Kingdom Medicines and Healthcare Products Regulatory Agency has approved the Marketing Authorization Application for its prostate cancer PET imaging agent Illuccix®.
Mobile Version